|
July. 30, 2020 |
|
|
Sept. 01, 2020 |
|
|
jRCTs051200038 |
Development of a new cancer diagnostic method based on metabolites derived from samples before and after oral administration of 13C-labeled glucose in patients with PET-positive lung cancer : Single-arm, exploratory clinical trial |
|
Search for new lung cancer biomarkers using 13C-labeled glucose |
Yoshida Masaru |
||
Kobe University Hospital |
||
7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo |
||
+81-78-382-6305 |
||
myoshida@med.kobe-u.ac.jp |
||
Yoshida Masaru |
||
Kobe University Hospital |
||
7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo |
||
+81-78-382-6305 |
||
myoshida@med.kobe-u.ac.jp |
Complete |
July. 30, 2020 |
||
| Aug. 24, 2020 | ||
| 6 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
diagnostic purpose |
||
(1) Patients who are at least 20 years old and under 80 years old at the time of obtaining consent |
||
(1) Patients with other cancers |
||
| 20age old over | ||
| 80age old not | ||
Both |
||
Resectable primary lung cancer |
||
Administration of 13C glucose |
||
primary lung cancer |
||
Identification of derived metabolites in blood and urine after 13C glucose administration |
||
Whether or not adverse events have occurred |
||
| Kobe University Clinical Research Ethical Committee | |
| 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, Hyogo | |
+81-78-382-6669 |
|
| cerb@med.kobe-u.ac.jp | |
| Approval | |
June. 30, 2020 |
none |